Being told you have an arrhythmia — whether atrial fibrillation, SVT, heart block, or another rhythm disturbance — raises immediate questions about treatment and what your medical aid covers. This guide focuses on the practical coverage questions.
Does My Medical Aid Have to Cover This?
Yes. Dysrhythmia is a CDL condition. Medications for heart rhythm management — rate-control drugs, rhythm-control drugs, and anticoagulants for AF — must be funded from the CDL benefit once registered. Acute hospital admissions for haemodynamically significant arrhythmias are covered under PMB.
Register for CDL Immediately
Contact the scheme's chronic disease department with:
- Cardiologist's letter confirming the diagnosis and ICD-10 code (I47–I49)
- Diagnostic confirmation — typically ECG, Holter monitor report, or cardiac event monitor recording
- CDL registration form
Once registered, ongoing medications are funded from CDL — not your MSA. For AF requiring lifelong anticoagulation, this distinction is substantial: NOAC therapy at R800–R850/month is a significant annual cost that the CDL benefit should absorb.
Anticoagulation: Warfarin vs NOACs
For AF, anticoagulation to prevent cardioembolic stroke is the most important pharmacological treatment. The choice is between:
Warfarin: INR-monitored; requires regular blood tests (every 4–6 weeks for stable patients); significant food and drug interactions. Inexpensive (~R80–R150/month). Available on virtually all CDL formularies.
NOACs (apixaban, rivaroxaban, dabigatran): No INR monitoring; fewer interactions; more convenient; current guideline preference. More expensive (~R750–R850/month). CDL formulary coverage varies by scheme — some schemes fund NOACs under CDL without exceptional-needs; others require authorisation; some defaulted on warfarin as CDL minimum.
If your cardiologist has prescribed a NOAC and the scheme is defaulting to warfarin, ask your cardiologist for a written clinical motivation explaining why warfarin is not preferred (e.g., labile INR, significant drug interactions, history of intracranial bleed, patient preference/lifestyle). Most schemes will approve NOACs with a motivated clinical letter.
Catheter Ablation: What to Expect
Catheter ablation is a curative or highly effective treatment for SVT and AF. For SVT, success rates exceed 90% and the procedure is often a one-time cure. For AF, success rates are lower and repeat procedures may be required.
Financial preparation for ablation:
- Total procedural cost: R60,000–R150,000 before specialist shortfall. The scheme covers at its approved rate (typically 100–200% of medical aid tariff for the procedure codes); the gap between the scheme rate and the electrophysiologist's actual fee is your shortfall.
- Electrophysiologist shortfall: R40,000–R120,000 depending on physician and complexity
- Gap cover: If you have gap cover, it will pay specialist shortfalls up to the OPL (~R220,000). This covers most ablation shortfall scenarios.
- Without gap cover: You will need to negotiate the shortfall directly with the electrophysiologist. Some physicians will accept the scheme rate; others will not.
Before booking an ablation, ask: What is the electrophysiologist's fee? What will the scheme pay? What is the gap and does my gap cover policy cover it?
Pacemaker Implantation
If your cardiologist recommends a permanent pacemaker for bradyarrhythmia or heart block:
- Request written pre-authorisation for the procedure, the device, and the implanting cardiologist separately
- Confirm whether the device is covered under the in-hospital benefit, a dedicated device benefit, or a combination — and whether there is a rand limit
- Ask the scheme for the scheme rate for the implanting cardiologist, and discuss the shortfall with your cardiologist's rooms in advance
- Arrange gap cover if not already in place
Device cost alone: R40,000–R120,000 depending on type. Shortfalls on the device plus specialist are the primary out-of-pocket exposure.
Living with AF: Monitoring and Ongoing Care
AF is a lifelong condition even when controlled. Ongoing management involves:
- Regular cardiologist review (typically 6–12 monthly when stable)
- Annual ECG and possibly echocardiogram to monitor cardiac structure
- Anticoagulation management (INR if warfarin; no routine blood test if NOAC)
- Awareness of symptoms suggesting deterioration (increasing breathlessness, palpitations, syncope, new stroke symptoms)
Stroke symptoms in an AF patient (speech difficulty, facial droop, arm weakness, sudden severe headache) require emergency care. Call an ambulance immediately.
Checklist
| Action | Priority |
|---|---|
| Register for CDL (ICD-10 I47–I49) | Immediate |
| Confirm anticoagulant (NOAC or warfarin) is CDL-funded | This week |
| Ask about NOAC CDL authorisation if prescribed | This week |
| Discuss ablation financial preparation with cardiologist | If ablation indicated |
| Confirm gap cover status before any procedure | Before procedure |
| Confirm pacemaker/device coverage in writing | Before any device implant |
Talk to Eldon
Get help understanding your plan options →
This page is general information about medical schemes. It is not medical advice: speak to a healthcare professional about your own treatment. Medical aid and gap cover advice is given by Eldon de Waal, a Supervised Representative of Approach Administration (FSP 23579).
Understanding Your Diagnostic Tests and Their Coverage
A full dysrhythmia workup commonly involves multiple investigations:
24–48 hour Holter monitor: Records every heartbeat over 1–2 days to capture paroxysmal arrhythmias that don't occur during a clinic ECG. Cost: R800–R1,800. Confirm it is covered under your diagnostic benefit.
Echocardiogram: Cardiac ultrasound to assess heart structure, function, and valve status — important for ruling out structural heart disease as a cause or consequence of arrhythmia. Cost: R2,000–R4,000.
Event monitor / extended recording: For arrhythmias that occur less often than a Holter can capture, a 30-day event monitor or implantable loop recorder (ILR) may be needed. ILR devices cost R15,000–R25,000. Pre-authorise explicitly and ask whether there is a cardiac device sub-limit under the in-hospital benefit.
Electrophysiology study (EPS): Invasive mapping study done in the catheterisation laboratory to characterise and localise the arrhythmia. Often combined with ablation in the same session. Cost before specialist shortfall: R30,000–R60,000 for EPS alone.
All these investigations should be pre-authorised where required. Ask your cardiologist's rooms to manage the authorisation process — they deal with the relevant codes and scheme requirements routinely.